WO1996008274A3 - Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie - Google Patents
Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie Download PDFInfo
- Publication number
- WO1996008274A3 WO1996008274A3 PCT/US1995/012205 US9512205W WO9608274A3 WO 1996008274 A3 WO1996008274 A3 WO 1996008274A3 US 9512205 W US9512205 W US 9512205W WO 9608274 A3 WO9608274 A3 WO 9608274A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- conjugates
- heparin
- targeted
- binding epidermal
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003102 growth factor Substances 0.000 title abstract 2
- 230000010005 growth-factor like effect Effects 0.000 title abstract 2
- 229960002897 heparin Drugs 0.000 title abstract 2
- 229920000669 heparin Polymers 0.000 title abstract 2
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 abstract 2
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000002254 cytotoxic agent Substances 0.000 abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001991 pathophysiological effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU37244/95A AU3724495A (en) | 1994-09-13 | 1995-09-13 | Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30577194A | 1994-09-13 | 1994-09-13 | |
US08/305,771 | 1994-09-13 | ||
US44197995A | 1995-05-16 | 1995-05-16 | |
US08/441,979 | 1995-05-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996008274A2 WO1996008274A2 (fr) | 1996-03-21 |
WO1996008274A3 true WO1996008274A3 (fr) | 1996-04-04 |
Family
ID=26974775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/012205 WO1996008274A2 (fr) | 1994-09-13 | 1995-09-13 | Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3724495A (fr) |
WO (1) | WO1996008274A2 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
CA2221269A1 (fr) * | 1995-05-16 | 1996-11-21 | Lois A. Chandler | Compositions contenant des acides nucleiques et des ligands pour un traitement therapeutique |
JP3840262B2 (ja) | 1995-10-23 | 2006-11-01 | ザ チルドレンズ メディカル センター コーポレイション | 治療用の抗血管新生組成物および方法 |
EP0923387B1 (fr) * | 1996-06-24 | 2001-09-26 | Selective Genetics, Inc. | Instruments medicaux recouverts d' heparine a usage intraveineux contenant des conjugues de facteur de croissance des fibroblastes |
US6838238B1 (en) * | 1996-10-17 | 2005-01-04 | Invitrogen Corporation | Morphatides: novel shape and structure libraries |
JP2002512259A (ja) * | 1998-04-17 | 2002-04-23 | ユニバーシティ・オブ・メリーランド, ボルティモア | 組換えヘパリン結合性上皮成長因子様成長因子(hb−egf)による間質性膀胱炎の治療方法 |
US7060433B1 (en) | 1999-11-12 | 2006-06-13 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening using diphtheria toxin constructs |
AU7579600A (en) * | 1999-09-14 | 2001-04-17 | Entremed, Inc | Method of producing and purifying endostatintm protein |
AU2904401A (en) * | 1999-11-12 | 2001-06-06 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening using diphtheria toxin constructs |
FR2805821B1 (fr) * | 2000-03-01 | 2004-01-16 | Diatos | Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires |
US8003595B2 (en) | 2000-03-01 | 2011-08-23 | Cellectis | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
WO2004096117A2 (fr) * | 2003-05-02 | 2004-11-11 | Xpression Antibody Therapeutics, Inc. | Systemes d'administration d'acides nucleiques |
WO2004096254A2 (fr) * | 2003-05-02 | 2004-11-11 | Xpression Antibody Therapeutics, Inc. | Compositions et procedes pour le traitement des tumeurs |
ATE533786T1 (de) | 2003-08-14 | 2011-12-15 | Cellectis | Aminosäuresequenzen, die das eindringen einer substanz von interesse in zellen und/oder zellkerne erleichtern |
US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
GB0718045D0 (en) | 2007-09-14 | 2007-10-24 | Peptcell Ltd | Pharmaceutical compound |
US9421245B2 (en) * | 2012-06-25 | 2016-08-23 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
CN116390932A (zh) * | 2020-06-24 | 2023-07-04 | 萨普雷米科技有限公司 | 用于在药品中使用的皂苷衍生物 |
IL299356A (en) * | 2020-06-24 | 2023-02-01 | Sapreme Tech Bv | hydrazone derivatives of saponin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006705A1 (fr) * | 1990-10-16 | 1992-04-30 | The Children's Medical Center Corporation | Mitogene de liaison d'heparine presentant une homologie avec le facteur de croissance epidermique (egf) |
WO1993025688A1 (fr) * | 1992-06-16 | 1993-12-23 | Whittier Institute For Diabetes And Endocrinology | Production recombinee de proteines contenant de la saporine |
WO1995003831A1 (fr) * | 1993-08-02 | 1995-02-09 | Prizm Pharmaceuticals, Inc. | Preparations monogenes de conjugues cytotoxiques |
WO1995024928A2 (fr) * | 1994-03-15 | 1995-09-21 | Prizm Pharmaceuticals, Inc. | Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil |
-
1995
- 1995-09-13 WO PCT/US1995/012205 patent/WO1996008274A2/fr active Search and Examination
- 1995-09-13 AU AU37244/95A patent/AU3724495A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006705A1 (fr) * | 1990-10-16 | 1992-04-30 | The Children's Medical Center Corporation | Mitogene de liaison d'heparine presentant une homologie avec le facteur de croissance epidermique (egf) |
WO1993025688A1 (fr) * | 1992-06-16 | 1993-12-23 | Whittier Institute For Diabetes And Endocrinology | Production recombinee de proteines contenant de la saporine |
WO1995003831A1 (fr) * | 1993-08-02 | 1995-02-09 | Prizm Pharmaceuticals, Inc. | Preparations monogenes de conjugues cytotoxiques |
WO1995024928A2 (fr) * | 1994-03-15 | 1995-09-21 | Prizm Pharmaceuticals, Inc. | Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil |
Non-Patent Citations (9)
Title |
---|
CHANDLER L. A. ET AL.: "CHARACTERIZATION OF MITOTOXINS CONTAING HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR FUSED TO SAPORIN.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 36, no. 0, pages 425 * |
CHEMICAL ABSTRACTS, vol. 121, no. 23, 5 December 1994, Columbus, Ohio, US; abstract no. 271455, MESRI, ENRIQUE A. ET AL: "The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans" * |
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; * |
E. A. MESRI ET AL.: "HEPARIN-BINDING TRANSFORMING GROWTH FACTOR ALPHA-PSEUDOMONAS EXOTOXIN A.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 7, 5 March 1993 (1993-03-05), MD US, pages 4853 - 4862, XP000578211 * |
EIGHTY-SIXTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, TORONTO,CANADA., 18 March 1995 (1995-03-18) - 22 March 1995 (1995-03-22) * |
J. CELL SCI. (1994), 107(9), 2599-608 CODEN: JNCSAI;ISSN: 0021-9533 * |
MICHAEL WESTBY ET AL.: "PREPARATION AND CHARACTERIZATION OF RECOMBINANT PRORICIN CONTAINING AN ALTERNATIVE PROTEASE-SENSITIVE LINKER SEQUENCE.", BIOCONJUGATE CHEMISTRY, vol. 3, WASHINGTON US, pages 375 - 381, XP002187830 * |
S. A. THOMPSON ET AL.: "CHARACTERIZATION OF SEQUENCES WITHIN HEPARIN-BINDING EGF-LIKE GROWTH FACTOR THAT MEDIATE INTERACTION WITH HEPARIN.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 4, 28 January 1994 (1994-01-28), MD US, pages 2541 - 2549, XP000578210 * |
ZHOU FEN ET AL.: "STRUCTURAL ORGANIZATION AND CHROMOSOMAL ASSIGNEMNET OF THE GEN ENCODING THE HUMAN HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR/DIPHTHERIA TOXIN RECEPTOR.", BIOCHEMISTRY, vol. 32, EASTON, PA US, pages 7932 - 7938 * |
Also Published As
Publication number | Publication date |
---|---|
WO1996008274A2 (fr) | 1996-03-21 |
AU3724495A (en) | 1996-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996008274A3 (fr) | Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie | |
EP0259904B1 (fr) | Thérapie anticancéreuse et médicaments cytotoxiques pour sa réalisation | |
US5502037A (en) | Pro-cytotoxic drug conjugates for anticancer therapy | |
EP0699766A1 (fr) | Protéines de fusion à base d'un anticorps thérapeutique avec facteur plaquettaire 4 | |
IL115517A0 (en) | Biologically active proteins | |
EP0954340A4 (fr) | Immunotherapie-cible associee contre le cancer | |
CA2053275A1 (fr) | Substances conjuguees a base de facteur de croissance de fibroblaste | |
CN104781271A (zh) | 具有生物可逆的基团的多核苷酸 | |
DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
HK1113579A1 (en) | Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12 | |
WO1988005077A1 (fr) | Procede pour modifier le metabolisme de cellules eucaryotes lors de l'incorporation de sequences etrangeres d'acides nucleique s au moyen d'un vecteur d'internalisation | |
CA2190752A1 (fr) | Facteurs de croissance proches de l'insuline modifies | |
US20080167370A1 (en) | Multidrug multiligand conjugates for targeted drug delivery | |
WO1998051325A3 (fr) | Peptides aleatoires se liant au recepteurs de transport du tractus gastrointestinal (git) et procedes y relatifs | |
ES2060947T3 (es) | Un nuevo sistema de suministro de anticuerpos para modificadores de la respuesta biologica. | |
ES2193143T3 (es) | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. | |
WO1999048536A3 (fr) | Apport local d'agents therapeutiques a action prolongee | |
Zhang et al. | Enhancing antitumor efficacy of nucleoside analog 5-fluorodeoxyuridine on HER2-overexpressing breast cancer by affibody-engineered DNA nanoparticle | |
AU6721998A (en) | Therapeutic use of the smr1 protein and active derivatives thereof | |
WO1997048804A3 (fr) | Ligands de recepteurs de tie-2 (ligands-3 tie; ligands-4 tie) et leurs utilisations | |
Mickisch et al. | Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice | |
Kan et al. | Receptor phenotype underlies differential response of hepatocytes and nonparenchymal cells to heparin-binding fibroblast growth factor type 1 (aFGF) and type 2 (bFGF) | |
WO2001008708A3 (fr) | Administration amelioree par l'intermediaire d'un recepteur du complexe enzyme inhibiteur de la serine protease | |
Tsuruo et al. | Enhanced cytocidal action of methotrexate by conjugation to concanavalin A | |
Okamoto et al. | Expression of fibroblast growth factor binding protein HBp17 in normal and tumor cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT.BUL.13/96 UNDER INID(54)"TITLE",REPLACE THE EXISTING TEXT BY"CONJUGATES OF HEPARIN-BINDING EPIDERMIAL GROWTH FACTOR-LIKE GROWTH FACTOR WITH TARGETED AGENTS" |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN Kind code of ref document: A3 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ KE |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |